--- title: "01:28 ETWorld's First CAR-T Therapy for Solid Tumors Available in China Soon" type: "News" locale: "en" url: "https://longbridge.com/en/news/282138215.md" description: "A groundbreaking CAR-T cell therapy for advanced gastrointestinal cancers is set to be available in China by mid-2026. Developed for solid tumors targeting Claudin18.2, this therapy, known as satri-cel (CT041), offers a new treatment option for patients with advanced gastric and pancreatic cancers. Clinical studies show a 41% objective response rate and improved progression-free survival compared to standard treatments. This therapy marks a significant advancement in cancer treatment, addressing a major unmet need for patients with limited options." datetime: "2026-04-09T05:30:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282138215.md) - [en](https://longbridge.com/en/news/282138215.md) - [zh-HK](https://longbridge.com/zh-HK/news/282138215.md) --- # 01:28 ETWorld's First CAR-T Therapy for Solid Tumors Available in China Soon _A New Hope for Patients with Advanced Gastric and Pancreatic Cancers_ , /PRNewswire/ -- A groundbreaking new **CAR-T cell therapy** for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients. The therapy, known as **satri-cel (CT041)**, is the **world's first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2**, a biomarker commonly found in gastric (stomach) and pancreatic cancers. **A New Era in Cancer Treatment** CAR-T therapy is a highly personalized treatment that uses a patient's own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time. While CAR-T has already transformed outcomes in blood cancers, this new therapy represents a **major breakthrough in treating solid tumors**, where effective options have historically been limited. **Promising Clinical Results** Clinical studies conducted in China have demonstrated encouraging outcomes for patients with advanced gastric and gastroesophageal cancers: - **Objective response rate (ORR): ~41%**, significantly higher than standard treatments - **More than 10x improvement vs. conventional therapies in some comparisons** - **Progression-free survival extended to ~4.7 months vs. ~1.7 months with standard care** These results have been presented at leading international conferences and published in top-tier medical journals, highlighting the global significance of this therapy. **Addressing a Major Unmet Need** Advanced gastric and pancreatic cancers remain among the most difficult cancers to treat, with limited effective options in later lines of therapy and poor survival outcomes. This CAR-T therapy offers a **new treatment pathway for patients who have exhausted conventional options**. **Who May Benefit** This therapy may be suitable for patients who: - Have **advanced or metastatic gastric or gastroesophageal cancer** - Have received **at least two prior lines of treatment** - Show **Claudin18.2-positive tumors** - Meet clinical eligibility criteria Each patient will undergo a detailed medical evaluation to determine suitability. **Looking Ahead** This therapy represents a **milestone in oncology**, opening the door for CAR-T treatments beyond blood cancers and into solid tumors. Ongoing research is exploring broader applications, including earlier-stage treatment and additional tumor types. **Contact Information** For more information, teleconsultation appointments and eligibility assessments please contact: Email: \[email protected\] WhatsApp: +852 4619 1904 Full article: https://jiahui.com/en/news/200 SOURCE Jiahui Health ### Related Stocks - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) ## Related News & Research - [Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape](https://longbridge.com/en/news/285930281.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)